Using Digital Tools to Advance Alzheimer’s Drug Trials During a Pandemic: The EU/US CTAD Task Force - 21/11/24
, P. Aisen 2, R. Amariglio 3, R. Au 4, C. Ballard 5, M. Carrillo 6, H. Fillit 7, T. Iwatsubo 8, G. Jimenez-Maggiora 2, S. Lovestone 9, F. Natanegara 10, K. Papp 3, M.E. Soto 11, M. Weiner 12, B. Vellas 13the EU/US CTAD Task Force
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
The 2020 COVID-19 pandemic has disrupted Alzheimer’s disease (AD) clinical studies worldwide. Digital technologies may help minimize disruptions by enabling remote assessment of subtle cognitive and functional changes over the course of the disease. The EU/US Clinical Trials in Alzheimer’s Disease (CTAD) Task Force met virtually in November 2020 to explore the opportunities and challenges associated with the use of digital technologies in AD clinical research. While recognizing the potential of digital tools to accelerate clinical trials, improve the engagement of diverse populations, capture clinically meaningful data, and lower costs, questions remain regarding the stability, validity, generalizability, and reproducibility of digital data. Substantial concerns also exist regarding regulatory acceptance and privacy. Nonetheless, the Task Force supported further exploration of digital technologies through collaboration and data sharing, noting the need for standardization of digital readouts. They also concluded that while it may be premature to employ remote assessments for trials of novel experimental medications, remote studies of non-invasive, multi-domain approaches may be feasible at this time.
Le texte complet de cet article est disponible en PDF.Key words : Alzheimer’s disease, clinical outcomes, digital tools, remote assessments
Plan
| EU/US/CTAD TASK FORCE: Sandrine Andrieu (Toulouse); Matthew Barton (Raleigh); Randall Bateman (Saint Louis); Monika Baudler (Basel); Joanne Bell (Willmington); Kevin Biglan (Indianapolis); Adam Boxer (San Francisco); Sasha Bozeat (Basel); Claudine Brisard (Issy les Moulineaux); Miroslaw Brys (Indianapolis); Marc Cantillon (Gilbert); Bill Chan (Beijing); Ivan Cheung (Woodcliff Lake); Min Cho (Woodcliff Lake); Julia Coelho (San Francisco); Shobha Dhadda (Woodcliff Lake); Daniel Di Giusto (Basel); Michael Donohue (San Diego); Rachelle Doody (Basel); John Dwyer (Washington); Michael Egan (North Wales); Rianne Esquivel (Malvern); Wendy Galpern (New Jersey); Harald Hampel (Woodcliff Lake); Jason Hassenstab (St Louis); David Henley (New Jersey); Joseph Herring (North Wales); Carole Ho (South San Francisco); Michael Irizarry (Woodcliff Lake); Keith Johnson (Boston); Geoffrey Kerchner (South San Francisco); Gene Kinney (South San Francisco); Shailaja Korukonda (Woodcliff Lake); Lynn Kramer (Woodcliff Lake); Jaren Landen (Cambridge); Ishani Landri (Woodcliff Lake); Lars Lannfelt (Uppsala); Valérie Legrand (Nanterre); Manoj Malhotra (Woodcliff Lake); Eric McDade (St Louis); Francisco Nogueira (South San Francisco); Gerald Novak (New Jersey); Gunilla Osswald (Stockholm); Susanne Ostrowitzki (South San Francisco); Amanda Paley (New York); Martin Rabe (Woodcliff Lake); Rema Raman (San Diego); Elena Ratti (Cambridge); Laurie Ryan (Bethesda); Stephen Salloway (Providence); Peter Schüler (Langen); Hiroshi Sekiya (Malvern); Jiong Shi (Las Vegas); Melanie Shulman (Cambridge); Eric Siemers (Zionsville); John Sims (Indianapolis); Kaycee Sink (South San Francisco); Reisa Sperling (Boston); Joyce Suhy (Newark); Jina Swartz (London); Pierre Tariot (Phoenix); Edmond Teng (South San Francisco); Jacques Touchon (Montpellier); Martin Traber (Basel); Andrea Vergallo (Woodcliff Lake); Judy Walker (Singapore); Jon Walsh (San Francisco); Alette Wessels (Indianapolis); Haichen Yang (North Wales); Wagner Zago (San Francisco); Kenton Zavitz (Cambridge). |
|
| Conflicts of interest: The Task Force was partially funded by registration fees from industrial participants. These corporations placed no restrictions on this work. Dr. Kaye reports grants from Merck, Eisai, Genentech, and Abbvie; and serves on a Data Safety Monitoring Committee at Eli Lilly. Dr. Aisen reports grants from Janssen, Eli Lilly, Eisai, NIA, the Alzheimer’s Association, and FNIH; and consulting fees from Biogen, Roche, Merck, Abbvie, Lundbeck, Proclara, and Immunobrain Checkpoint. Dr. Amariglio declares there are no conflicts. Dr. Au is on the scientific advisory board of Signant Health and a consultant to Biogen. Dr. Ballard reports grants from Arcadia pharmaceutical company and Lundbeck; personal fees from Arcadia, Lundbeck, Roche, Otsuka, Novartis, Eli Lilly, Suven, Sunovion, ADDEX, and Exciva; personal fees and other from Synexus, Novo Nordisk; and consulting fees from Biogen. Dr. Carillo declares there are no conflicts. Dr. Fillit declares there are no conflicts. Dr. Iwatsubo declares there are no conflicts. Dr. Jimenez-Maggiora declares there are no conflicts. Dr. Lovestone is an employee of Janssen Medical Ltd and a co-founder of Akrivia Health Ltd. Dr. Natanegara is an employee of Eli Lilly and Company. Dr. Papp declares there are no conflicts. Dr. Soto declares payment as consultant or advisor from Avanir, Acadia. Dr. Weiner reports grants from Siemens, Biogen, and Johnson & Johnson, NIH, California Department of Health, University of Michigan, Hillblom Foundation, Alzheimer’s Association, State of California, Kevin and Connie Shanahan, GE, VUMc, American Catholic University, The Stroke Foundation, and the Veteran’s Administration; has served on advisory boards for Eli Lilly, Cerecin/Accera, Roche, Alzheon Inc., Merck Sharp & Dohme Corp, Nestle/Nestec; and has consulted with or acted as a speaker to Cerecin/Accera Inc., BioClinica, Nestle/Nestec, Genentech, FUJIFILM-Toyama Chemical, and T3D Therapeutics; and holds stock options with Alzheon Inc, Alzeca, and Anven. Dr. Vellas reports grants from Lilly, Merck, Roche, Lundbeck, Biogen, grants from Alzheimer’s Association, European Commission, personal fees from Lilly, Merck, Roche, Biogen, outside the submitted work. |
Vol 8 - N° 4
P. 513-519 - avril 2021 Retour au numéro
Article précédent
- Cohort-Specific Optimization of Models Predicting Preclinical Alzheimer’s Disease, to Enhance Screening Performance in the Middle of Preclinical Alzheimer’s Disease Clinical Studies
- K. Sato, T. Mano, R. Ihara, K. Suzuki, Y. Niimi, T. Toda, T. Iwatsubo, Atsushi Iwata, Alzheimer’s disease Neuroimaging Initiative, Japanese Alzheimer’s disease Neuroimaging Initiative, The A4 Study Team
- Comparative Efficacy, Safety, Tolerability, and Effectiveness of Antipsychotics in The Treatment of Dementia-Related Psychosis (DRP): A Systematic Literature Review
- I. Yunusa, N. Rashid, V. Abler, Krithika Rajagopalan
Bienvenue sur EM-consulte, la référence des professionnels de santé.